Agrow is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cellectis gains exclusive licence to CRISPR gene tool

French genomics company Cellectis' US subsidiary, Cellectis Plant Sciences (New Brighton, Minnesota), has signed a licensing agreement with the University of Minnesota over a novel gene editing technology. It grants Cellectis exclusive worldwide rights to the patent, WO/2014/144155, covering "engineering plant genomes using CRISPR [clustered regularly interspaced short palindromic repeats]/Cas [CRISPR associated] systems". In addition to meganucleases and TALEN (transcription activator-like effector nucleases) technology, this approach for targeted modification of plant genomes was developed by the laboratory of Professor Dan Voytas, Cellectis points out.  It enables a number of useful tools to target specific loci in a genome and/or modulate the expression of genes, the company notes. The technology is based on novel sequence-specific nucleases that can be cheaply engineered to recognise any gene of interest in a genome. As with other gene editing tools, its application could lead to the development of valuable crops, Cellectis

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG022220

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel